About a-team Marketing Services
The knowledge platform for the financial technology industry
The knowledge platform for the financial technology industry

A-Team Insight Blogs

CFTC and SEC Divvy up Derivatives Pie, CME’s Donohue Expresses Concern About Illiquid Derivatives

Subscribe to our newsletter

Following a brief hiatus, the turf war is back on between the Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC). Just how the two regulators will divide up the oversight of the derivatives market is currently being debated across the industry and could have wide ramifications for those involved in the sector.

SEC chairman Mary Schapiro is keen to get more authority over more OTC products including securities related swaps, and has been vigorously lobbying Congress over the last week to that end. “Primary responsibility for securities related OTC derivatives would be retained by the SEC, which is also responsible for oversight of markets affected by this subset of OTC derivatives,” Schapiro said in testimony before the Senate Banking Subcommittee on Securities earlier this week.

She contended that oversight of foreign exchange, interest rate and commodity swaps should be the remit of the CFTC, while the Fed should oversee systemically important banks that are involved in the derivatives business. Schapiro stressed that firms should not be subject to duplicative oversight processes: “OTC derivatives dealers that are banks would be subject to prudential supervision by their federal banking regulator. All other OTC derivatives dealers in securities related OTC derivatives would be subject to supervision and regulation by the SEC.”

This is a rather difficult proposition given the circumstances and it also sustains the current confusing patchwork of regulatory oversight in the country. Turf battles are likely to reoccur in the future as regulators are forced to negotiate which financial institutions fall under their remit. The likely impact on these firms is the imposition of more onerous reporting requirements by regulators seeking to prove their competence. Duplicative reporting processes may also be maintained and this could have a significant impact on their compliance, record keeping and reporting systems.

The plans will also require all standardised OTC products to go through clearing houses in order to reduce counterparty risk in the market. Moreover these products will also be required to be traded by electronic execution methods, whereas more complex OTC derivatives will be subject to new mandatory reporting requirements. This data on complex products would then be stored in a trade repository for regulatory reference purposes.

The plan for clearing OTC derivatives has stirred up some controversy in the market already. For example, this week, Craig Donohue, chief executive of CME Group, indicated that he believes it would be dangerous for all these products to be forced into being cleared electronically. “We have to be careful to manage the risk profile of what we clear and there will be a range of things that we would not be comfortable clearing,” he warned.

Donohue is keen for the market to have some sway in deciding what is centrally cleared, rather than being forced to clear all standardised trades. “We want to be able to make the decision to clear what we feel comfortable with from a risk perspective,” he said.

These concerns are warranted and, given the focus on systemic risk, are likely to be seconded by a number of other participants in the market. However, much like deciding how big each regulator’s share of the derivatives pie will be, it will be up to the powers that be to decide whether these warnings are heeded.

Subscribe to our newsletter

Related content

WEBINAR

Recorded Webinar: Mastering Data Lineage for Risk, Compliance, and AI Governance

Financial institutions are under increasing pressure to ensure data transparency, regulatory compliance, and AI governance. Yet many struggle with fragmented data landscapes, poor lineage tracking and compliance gaps. This webinar will explore how enterprise-grade data lineage can help capital markets participants ensure regulatory compliance with obligations such as BCBS 239, CCAR, IFRS 9, SEC requirements...

BLOG

Regulations in the Balance as Institutions Remain Sustainability-Focussed: ESG Summit London Review

Despite a perception that ESG is in retreat around the world, financial institutions continue to take the issue very seriously as a matter of risk management, a trend that continues to exert an influence on the data demands of organisations. It isn’t even the compliance imperatives of organisations operating in heavily regulated parts of the...

EVENT

RegTech Summit London

Now in its 9th year, the RegTech Summit in London will bring together the RegTech ecosystem to explore how the European capital markets financial industry can leverage technology to drive innovation, cut costs and support regulatory change.

GUIDE

AI in Capital Markets: Practical Insight for a Transforming Industry – Free Handbook

AI is no longer on the horizon – it’s embedded in the infrastructure of modern capital markets. But separating real impact from inflated promises requires a grounded, practical understanding. The AI in Capital Markets Handbook 2025 provides exactly that. Designed for data-driven professionals across the trade life-cycle, compliance, infrastructure, and strategy, this handbook goes beyond...